Jazz Pharmaceuticals plc — Director's Dealing 2026

Mar 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2026-02-26

Reporting Person: Patil Neena M (EVP & Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Ordinary Shares	M	20125	$113.1	Acquired	73464	Direct
2026-02-26	Ordinary Shares	S	16602	$192.5271	Disposed	56862	Direct
2026-02-26	Ordinary Shares	M	875	$113.1	Acquired	57737	Direct
2026-02-26	Ordinary Shares	S	875	$192.0651	Disposed	56862	Direct
2026-02-26	Ordinary Shares	M	27084	$137.12	Acquired	83946	Direct
2026-02-26	Ordinary Shares	S	15555	$190.2801	Disposed	68391	Direct
2026-02-26	Ordinary Shares	M	2916	$137.12	Acquired	71307	Direct
2026-02-26	Ordinary Shares	S	2916	$189.8117	Disposed	68391	Direct
2026-02-26	Ordinary Shares	A	10079	$0.0	Acquired	78470	Direct
2026-02-26	Ordinary Shares	S	11529	$191.6455	Disposed	66941	Direct
2026-02-26	Ordinary Shares	S	3523	$193.5831	Disposed	63418	Direct
2026-02-26	Ordinary Shares	S	1061	$190.0035	Disposed	62357	Direct
2026-02-26	Ordinary Shares	S	549	$190.7963	Disposed	61808	Direct
2026-02-26	Ordinary Shares	S	1784	$191.8789	Disposed	60024	Direct
2026-02-26	Ordinary Shares	S	1009	$192.7915	Disposed	59015	Direct
2026-02-26	Ordinary Shares	S	197	$193.5982	Disposed	58818	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Incentive Stock Option (right to buy)	$113.1	M	875	Disposed	2030-02-26	Ordinary Shares (875)	Direct
2026-02-26	Incentive Stock Option (right to buy)	$137.12	M	2916	Disposed	2029-08-07	Ordinary Shares (2916)	Direct
2026-02-26	Non-Qualified Stock Option (right to buy)	$113.1	M	20125	Disposed	2030-02-26	Ordinary Shares (20125)	Direct
2026-02-26	Non-Qualified Stock Option (right to buy)	$137.12	M	27084	Disposed	2029-08-07	Ordinary Shares (27084)	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F6: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F8: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F9: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F10: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F11: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F12: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F13: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F14: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.